Infection of long-lived CD4 þ T cells is a major obstacle to HIV remission, and antiretroviral therapy (ART) instituted during acute HIV infection restricts HIV reservoir establishment. Broadly neutralizing antibodies (bNAbs) may be employed in conjunction with early ART as strategies toward HIV remission.
INTRODUCTION
Several lines of evidence indicate that immunebased therapy will be key to achieving HIV remission, that is, control of plasma viremia to undetectable levels in the absence of antiretroviral therapy (ART) [1,2 && ,3 && ,4,5]. Studies of broadly neutralizing antibodies (bNAbs) in vitro and in animal models demonstrate the ability of these agents to reduce the frequencies of cells harboring viral DNA in the peripheral blood and in tissue, and to suppress plasma viremia, with remission achieved in a subset of animals [3 && ,6 && ,7,8 && ]. There are several studies planned in humans that will evaluate the effects of bNAbs on HIV viremia, reservoirs, and remission.
bNAbs' functionality lies in their ability to bind and clear both cell-free virus and viral-infected cells. How to optimally use bNAbs in humans is unclear. Although the animal models of bNAbs thus far involved chronically infected animals, bNAbs may be best used in acute HIV infection, either before ART or after viral suppression and HIV reservoir attenuation from early ART. Long-term virally suppressed, chronically infected patients have large HIV reservoirs so it seems daunting that such passive antibody administration could decrease these reservoirs enough for HIV remission to be possible. In contrast, the acute HIV infection period presents a unique opportunity to explore the use of bNAbs with ART to contain viral replication and limit the HIV reservoir seeding that may enhance the chance for HIV remission.
In this article, we discuss HIV reservoir establishment during acute HIV infection, the effects of early ART on HIV reservoirs, and the studies of bNAbs on lentivirus reservoirs in animal models and those that are planned in humans. Finally, we propose research strategies for bNAbs in acute HIV infection aiming at HIV reservoir attenuation and HIV remission.
HIV reservoir establishment during acute HIV infection and after early antiretroviral therapy HIV preferentially infects activated CD4 þ T cells that are then killed by effector T cells or they undergo apoptosis or pyroptosis [9] [10] [11] . However, a very small proportion of these cells reverts to a resting state that allows them to evade host immune responses to HIV infection and persist indefinitely despite many years of suppressive antiviral treatment. These resting CD4 þ T cells, predominantly, central memory CD4 þ T cells, may also be infected directly. Their maintenance is thought to be primarily from homeostatic proliferation [12] .
It is clear that the HIV reservoir which enables persistence occurs early in infection but the precise timing is unknown [13] . A recent study in rhesus macaques showed that simian immunodeficiency virus (SIV) infection with effective ART initiated at day three and prior to detectable viremia did not prevent the development of a latent reservoir nor viral rebound when it was later removed [14] . Early ART, however, did reduce the frequencies of cells harboring SIV, which was corroborated in another study of early treated rhesus macaques showing that treatment before peak viremia was key in reducing the reservoir size [15] . Notable is that the route and dose of SIV challenge result in far more efficient transmission than HIV in humans, and the rhesus macaque model lacks certain host restriction factors and therefore this model may not be directly applicable to humans.
It has been shown since the 1990s that latently infected cells were readily detected in people with recent HIV infection, that is those infected within the past 6-12 months [13] . What was lacking, however, was information on HIV reservoir establishment during very early stages of HIV or acute HIV infection when HIV immunoglobulin (Ig)G is not yet detected. This is due in part to the challenge of identifying acute HIV infection that requires testing to be done during a short-window period prior to antibody detection by routine methods, and the expense of algorithmic testing using sensitive antigen-antibody combo testing and/or nucleic acid testing. Recent data demonstrated a gradual increase in cell-associated HIV DNA in blood and gut during the first month of infection, with the lowest reservoir size observed in individuals diagnosed before HIV IgM developed, which roughly corresponded to the first 2-3 weeks of infection [16] . These individuals also exhibit the lowest reservoir size following early ART [17, 18] .
ART instituted during acute HIV infection does not eliminate HIV persistence, but it significantly restricts infection and facilitates a faster decay of latently infected cells [19] [20] [21] . Importantly, it attenuates infection of long-lived central memory CD4 þ T cells [18, 22] and may skew the distribution of latently infected cells to shorter-lived memory CD4 þ T cells that are more prone to immune clearance, a profile observed in posttreatment controllers in the VISCONTI cohort [23] and in long-term nonprogressors [24] .
Broadly neutralizing antibody and the HIV reservoir
Single or combination administration of bNAbs has the potential to combat HIV infection by preventing viral spread, facilitating viral clearance, and mediating destruction of virus-producing cells, which, in turn, decreases the viral reservoir and reduces immune activation [25] .
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KEY POINTS
Infection of resting and long-lived CD4 þ T cells occurs during acute HIV infection. These cells can persist indefinitely, posing a major obstacle to HIV remission. ART instituted during acute HIV infection can restrict the HIV reservoir size in the peripheral blood and tissues. bNAbs clear cell-free virus and infected cells that express HIV. They have been shown in animal models to reduce viremia and frequencies of infected cells in the peripheral blood and tissue compartments. If, and how, bNAbs can eliminate latently infected cells is not well understood.
Research strategies could include employing bNAbs in conjunction with ART in acute HIV infection to reduce HIV viral burden. They could also be given to virally suppressed individuals who initiated ART during acute HIV infection with a goal to eliminate persistently infected cells and prolong time to viral rebound in the absence of ART.
Broadly neutralizing antibody and HIV reservoir Ananworanich et al. bNAbs were administered in mice 2-3 weeks postinfection, and viral inducers were administered once plasma-viremia and cell-associated HIV RNA dropped below the limit of detection In chronically infected hu-mice with suppressed viremia, 10 of 23 showed viral rebound after administration of all three viral inducers simultaneously with tri-mix bNAbs, compared to 31 of 33 hu-mice exhibiting viral rebound after tri-mix therapy þ any single inducer (P ¼ When bNAb was given with ART to lower the initial viral load followed by a tri-mix bNAb immunotherapy during ART interruption, it prevented viral rebound in five of five hu-mice in the presence of the bNAb mixture. Whereas the mice that only received ART, all rebounded when ART was stopped. Control of plasma viremia during period of bNAb monotherapy correlated with bNAb half-life
When bNAb is given with ART to lower initial viremia, it allowed maintenance bNAb immunotherapy to prevent viral load rebound when ART is discontinued
In one arm of the study, mice were treated for 6 weeks with combination immunotherapy (PG16, 3BNC117, 10-1074)
2-3 weeks after infection
In the other arm of the study, HIV-1 YU2 infected mice were Indian origin rhesus macaques that did not express MHC class I alleles Mamu-AÃ01, Mamu-BÃ08, Mamu-BÃ17. ]. Phase I dose-finding and safety studies in humans are being performed for Vaccine Research Center (VRC)01 [27, 28] and 3BNC117 bNAbs [29] . Several planned studies in adults and children will evaluate the effects of VRC01 bNAb on the HIV reservoirs including two by the U.S. Military HIV Research Program that will evaluate the use of VRC01 in acutely infected individuals (Retrovirology (RV)397 and RV398 studies).
How might broadly neutralizing antibody be tested in acute HIV infection to achieve HIV reservoir reduction and remission?
The recent identification and characterization of several classes of bNAbs provides an opportunity to study these agents for HIV treatment. Figure 1 illustrates two research strategies that unified in their focus on individuals identified during acute HIV infection but direct those interventions at different timepoints in the disease course. First, bNAbs could be used in combination with ART during acute HIV infection when viral load rise is rapid and extreme, based on the hypothesis that the bNAbs could exhibit a synergistic effect with ART on reducing viral burden. This may quickly suppress plasma viral load and limit establishment of latent viral reservoirs across multiple compartments. Secondly, individuals who were identified and treated with ART during acute HIV infection could be administered bNAbs to facilitate clearance of HIV-infected, and, presumably latently infected cells, in order to enhance their ability to control viremia post-ART interruption. Such individuals may have limited HIV-specific immunity because of efficient suppression of HIV viremia with early ART, and may benefit from adjunct immunotherapy like bNAb. It is conceivable that administrating LRAs, such as histone deacetylase inhibitors or newer drug classes, prior to bNAbs could reactivate viral production from, and HIV expression on, the latently infected cells to further promote the elimination of these reactivated cells by bNAbs. Other immune-based therapies such as T-cell-based therapies, therapeutic HIV vaccines, or immune checkpoint blockers [4] could also be tested in combination with bNAbs at the time of acute HIV infection or after viral suppression.
Many questions arise from these research designs. How do we optimally quantify the changes in HIV reservoir size and composition following bNAbs? What types of sampling should be done? How often and how long should the bNAbs be given? At this time, there are no clear answers. Quantifying the HIV reservoir in PBMCs are limited by the sensitivity of available assays [30, 31] . Lessons are learned from the reemergence of virus in three patients after several months to 2.5 years off treatment, who previously had no detectable HIV DNA or replication-competent virus [32] [33] [34] . The absence of predictive markers for rebound in the plasma or PBMC suggests the need to measure HIV in tissue, which is more difficult because of limitations in sampling and low viable cell yield. In these early trials, it seems prudent to measure cell-associated HIV DNA and HIV RNA, replication-competent virus and low-level viremia in the peripheral blood and tissue compartments, and store samples for future testing.
The bNAbs are currently administered intravenously or subcutaneously, and their half-lives vary. It is possible that administration as frequent as every 2-4 weeks may be needed. The duration of bNAbs will depend on trial designs. When given in addition to ART during acute HIV infection to reduce viral burden, one to two doses may be adequate. When the goal is to achieve HIV remission, more doses may be required to control viremia following ART interruption. Frequent administrations, however, could promote viral escape or elicit antibody to bNAbs, rendering bNAbs ineffective [2 && ,7,35]. The use of multiple bNabs with different specificities is attractive and some data indicate these combinations will be superior. Notably though, the potency and breadth of bNAbs are HIV cladespecific, for example, glycan-dependent bNAbs such as PGT121 have little activity against HIV CRF01_AE recombinant that circulates in Thailand and some Asian countries.
FUTURE RESEARCH
The fundamental research question is whether bNAb can kill latently infected cells. The conventional belief is that latently infected resting cells express no HIV on their surface rendering them incapable of being detected and bound by bNAbs, as observed with natural immune surveillance. However, reduction in cell-associated viral DNA by bNAb has been shown in some studies [3 && ,6 && ], but that may be due to shortening of infected cell half-life and blocking of viral spread [6 && ]. Research to extensively characterize cells able to be cleared by bNAbs will help to elucidate this important question. Another critical question is the extent to which bNAbs can affect tissue reservoirs. Although these antibodies are believed to have poor tissue penetration, containment of reservoirs in these compartments was observed in one study in macaques [3 && ]. For bNAbs to have a significant effect on HIV reservoir and remission, understanding their activities in lymphoidassociated tissues (e.g. lymph nodes and gut), and in the central nervous system, is a high priority research area. Key bNAb FIGURE 1. Proposed research strategies for using broadly neutralizing antibody (bNAb) in acute HIV infection. In the typical course of HIV infection (grey line), HIV RNA peaks during acute infection, penetrates various body compartments to establish a latent reservoir, and ultimately reaches a steady level of viremia. Antiretroviral therapy (ART) initiated during chronic infection reduces HIV RNA, often to undetectable levels, but the virus rebounds when ART is stopped. bNAbs can be administered with ART during acute infection in order to possibly achieve a more rapid viral suppression (black line) and prevent establishment of a significant HIV reservoir. In people treated with ART during acute HIV infection, bNAbs could be given in attempt to eliminate HIV-infected cells to an extent that, thereby, viremic control posttreatment interruption can be achieved (dark grey line). It is also possible to give latency reversing agents (LRAs) to reactivate the expression of HIV on infected cells to facilitate the bNAb's function in eliminating these reactivated cells.
CONCLUSION
Intervening during acute HIV infection with ART has been one of the most effective ways to attenuate HIV reservoir seeding. HIV reservoir size (frequency of cells harboring HIV DNA or replication-competent virus) is to date, the best, albeit imperfect, surrogate marker for time to viral load rebound in the absence of ART [36] [37] [38] . However, early ART alone is inadequate in achieving sustained viral remission as illustrated in the Mississippi child [32, 33] . Therefore, combination cure therapy, akin to combination ART for HIV, will likely be required to achieve this goal. Perhaps, the most important research question facing the HIV cure field is the choices of combination therapy to advance into clinical trials. ART will continue to be the main stay of HIV treatment but bNAbs may have an important contributing role toward an HIV remission, particularly when given in the setting of low HIV reservoirs, such as in acute HIV infection. Research into delivering durable bNAbs by active immunization with novel viral-like particle immunogens or adeno-associated virus vector is underway [39, 40] . The bNAbs could also be tested in combination with LRAs or other immune-based therapies. However, testing more than one novel therapy in HIV cure research is challenging at many levels. Understanding the contribution of individual agents to the efficacy and safety outcomes will be difficult and agents with no effect alone may provide synergy in combination strategies. The risk to trial participants would be theoretically greater with combination agents, but the likelihood of success may also be higher. Requirements for approval of combination cure therapies by regulator agencies are unclear. Partnership between companies may be complicated based on intellectual property and marketing considerations. Finally, measurement of success requires an interruption of suppressive treatment and observation. Defining a surrogate marker for rebound will greatly accelerate the evaluation of cure strategies including those using bNAbs.
Eradicating every cell capable of producing HIV is extremely difficult and currently unachievable in the absence of extreme measures such as the cancer treatment and bone marrow transplantation with HIV resistant cells used in the Berlin patient [41] .
The alternate goal of HIV remission is realistic and achievable. Early ART in conjunction with immunebased interventions such as bNAbs offers hope in realizing this goal and warrants their advancement into clinical trials.
